A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Conditions: Breast Cancer Interventions: Drug: [68Ga]Ga-NeoB; Drug: [177Lu]Lu-NeoB; Drug: Capecitabine Sponsors: Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | HER2 | Research | Study | Xeloda